News

Us2.ai, Duke University team up to develop better tools using AI

A joint initiative between a Singapore-based medical technology company and Duke University is aiming to develop and commercialize artificial intelligence, or AI, tools for echocardiography — using ultrasounds to visualize the heart. Researchers from Us2.ai, the first new company created from an 11-country cardiovascular research platform, have teamed up…

Gradient raises €14M in support of ultrasound-based device for PH

Gradient Denervation Technologies has raised €14 million (around $14.9 million) in funding to support the clinical development and testing of an ultrasound-based catheter device for the treatment of pulmonary hypertension (PH). The minimally invasive catheter device is designed for use in the pulmonary arteries. It delivers therapeutic ultrasound…

Sotatercept improves blood flow, heart health in PAH: STELLAR trial

Treatment with sotatercept in addition to standard pulmonary arterial hypertension (PAH) therapies significantly improved measures of heart health for adults with the disease, according to a new analysis of the STELLAR trial. Results from the Phase 3 trial had already shown the therapy enhanced walking abilities in the participants…

People with severe CTEPH see improved risk profile with treprostinil

Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The risk profile was assessed using a risk score established to predict a response to treatment and survival in people with pulmonary arterial hypertension (PAH), the most common type…

Janssen stops Phase 3 trial testing high-dose Opsumit in CTEPH

A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early after an analysis showed the treatment is unlikely to help patients. The announcement was made in a press release from Janssen, the company that markets Opsumit. Opsumit…

AI Therapeutics begins dosing in Phase 2 trial of LAM-001

AI Therapeutics has begun dosing in a clinical trial testing inhaled LAM-001, a potential disease-modifying therapy for pulmonary arterial hypertension (PAH). The 24-week, open-label Phase 2 study (NCT05798923) is recruiting 15 adults at Brigham and Women’s Hospital in Boston, Massachusetts. All participants should have advanced PAH…

Key gene, protein changes seen in people with PoPH in new study

Scientists have identified gene, protein, and signaling pathway alterations in the livers of people with portopulmonary hypertension (PoPH) — a form of pulmonary arterial hypertension (PAH) usually associated with liver disease — that could reflect underlying mechanisms of the rare disorder. Compared with liver disease patients without PoPH, those…

Breathing workout strengthens muscles, exercise capacity: Study

Engaging in inspiratory muscle training for eight weeks may help people with pulmonary hypertension (PH) strengthen their respiratory (breathing) muscles and gain exercise capacity, a study suggests. This is important because inspiratory (breathing in) muscle training may offer a non-invasive approach to improve the quality of life and overall…

Echocardiography useful in detecting PH, predicting its course

Echocardiography, a noninvasive imaging method to examine heart structure and function, can be useful in making a preliminary diagnosis of pulmonary hypertension and in determining its likely course, according to a review study. “In future, it is important to use multiple echocardiographic parameters for detection and predicting the prognosis…